{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:48:28Z","timestamp":1760921308118,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":276,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["3A0241","3A0242","370651","370652","370653"],"award-info":[{"award-number":["3A0241","3A0242","370651","370652","370653"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Health, Taiwan","award":["DOH100-TD-B-111-005","DOH101-TD-B-111-005"],"award-info":[{"award-number":["DOH100-TD-B-111-005","DOH101-TD-B-111-005"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.tjog.2014.04.027","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T03:47:02Z","timestamp":1430365622000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunomodulatory therapy in refractory\/recurrent ovarian cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"Chao-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Hsin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Hsueh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2014.04.027_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"year":"2011","series-title":"Cancer Registry Annual Report, 2009. Taiwan","key":"10.1016\/j.tjog.2014.04.027_bib2"},{"key":"10.1016\/j.tjog.2014.04.027_bib3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2014.04.027_bib4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2004.07.008","article-title":"Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer","volume":"95","author":"McMeekin","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib7","first-page":"309","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tjog.2014.04.027_bib8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","article-title":"Immunotherapy for ovarian cancer: what's next?","volume":"29","author":"Kandalaft","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2014.04.027_bib10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.tjog.2014.04.027_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2009.09.042","article-title":"Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study","volume":"116","author":"Recchia","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2009.11.001","article-title":"The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade","volume":"116","author":"Kandalaft","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib13","first-page":"3295","article-title":"Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy","volume":"24","author":"Ryoma","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.tjog.2014.04.027_bib14","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1158\/0008-5472.CAN-07-0565","article-title":"Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma","volume":"67","author":"Wei","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.tjog.2014.04.027_bib15","first-page":"669","article-title":"Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in\u00a0vivo without significant toxicity","volume":"2","author":"Meropol","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2014.04.027_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.cco.0000142070.45097.68","article-title":"A\u00a0review of recent findings involving interleukin-2-based cancer therapy","volume":"16","author":"Eklund","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib17","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2014.04.027_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.tjog.2014.04.027_bib19","unstructured":"Food and Drug Administration, Department of Health, Executive Yuan, Taiwan http:\/\/www.fda.gov.tw. Web. [12.12.13]."},{"key":"10.1016\/j.tjog.2014.04.027_bib20","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0090-8258(03)00471-2","article-title":"Optimal sequencing in the treatment of recurrent ovarian cancer","volume":"90","author":"Spriggs","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2014.04.027_bib22","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2014.04.027_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]","volume":"96","author":"Rustin","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2014.04.027_bib24","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2005.10.027","article-title":"Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up","volume":"101","author":"Chou","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib26","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/bjc.1994.33","article-title":"Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease","volume":"69","author":"Seymour","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tjog.2014.04.027_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/07357907.2012.657812","article-title":"Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer","volume":"30","author":"Garcia","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.tjog.2014.04.027_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2008.04.037","article-title":"Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium","volume":"110","author":"Goff","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib34","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2014.04.027_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e32835a5ca3","article-title":"Management of toxicities associated with high-dose interleukin-2 and biochemotherapy","volume":"24","author":"Poust","year":"2013","journal-title":"Anticancer Drugs"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455915000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455915000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:13:18Z","timestamp":1760897598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455915000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1028455915000273"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2014.04.027","relation":{},"ISSN":["1028-4559"],"issn-type":[{"type":"print","value":"1028-4559"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory therapy in refractory\/recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2014.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}